Plasma Gamma-Glutamyltransferase Is Strongly Determined by Acylation Stimulating Protein Levels Independent of Insulin Resistance in Patients with Acute Coronary Syndrome

Background.Steatosis is a manifestation of the metabolic syndrome often associated with release of liver enzymes and inflammatory adipocytokines linked to cardiovascular risk. Gamma-glutamyltransferase (GGT) is one sensitive liver marker recently identified as an independent cardiovascular risk factor. Mechanisms involved in enhanced hepatic lipogenesis causing steatosis are not yet identified and are usually linked to insulin resistance (IR). Acylation stimulating protein (ASP), a potent lipogenic factor, was recently shown to increase in patients with steatosis and was implicated in its pathogenesis.Aim.To investigate the association of plasma ASP levels with liver and metabolic risk markers in acute coronary syndrome (ACS) patients.Methods.28 patients and 30 healthy controls were recruited. Their anthropometrics, lipid profile, liver markers, insulin, and ASP levels were measured.Results.In the patients, ASP, liver, and metabolic risk markers were markedly higher than in the controls. ASP strongly predicted GGT levels (B=0.75,P<0.0001), followed by triglycerides (B=0.403,P=0.017), together determining 57.6% variation in GGT levels. Insulin and IR correlated with metabolic risk components but not with liver enzymes.Conclusion.The strong association of ASP with GGT in ACS patients suggests that ASP, independent of IR, may contribute to a vicious cycle of hepatic lipogenic stimulation and GGT release promoting atherogenesis.

Download Full-text

The Decreased Growth Hormone Response to Growth Hormone Releasing Hormone in Obesity Is Associated to Cardiometabolic Risk Factors

Mediators of Inflammation ◽

10.1155/2010/434562 ◽

2010 ◽

Vol 2010 ◽

pp. 1-8 ◽

Cited By ~ 18

Author(s):

Fernando Cordido ◽

Jesús Garcia-Buela ◽

Susana Sangiao-Alvarellos ◽

Teresa Martinez ◽

Ovidio Vidal

Keyword(s):

Insulin Resistance ◽

Growth Hormone ◽

Cardiovascular Risk ◽

Ldl Cholesterol ◽

Premenopausal Women ◽

Fasting Insulin ◽

Risk Markers ◽

Obese Women ◽

Gh Secretion ◽

The Metabolic Syndrome

The aim of the present study was to evaluate the relationship between GHRH-induced GH secretion in obese premenopausal women and cardiovascular risk markers or insulin resistance. Premenopausal obese women, aged 35–52 years, were studied. GH secretion, IGF-I, serum cardiovascular risk markers, insulin, leptin, mid-waist and hip circumference, total body fat, and truncal fat were measured. Subjects were classified as meeting the criteria for GH deficiency (GHD) when peak GH after stimulation with GHRH was≤3 μg/L. Mean total and LDL cholesterol, fasting insulin, and HOMA-IR were all higher, in subjects who would have been classified as GH-deficient compared with GH-sufficient. Peak GH secretion after stimulation was inversely associated with fasting insulin (R=−0.650,P=.012), HOMA-IR (R=−0.846,P=.001), total cholesterol (R=−0.532,P=.034), and LDL cholesterol (R=−0.692,P=.006) and positively associated with HDL cholesterol (R=0.561,P=.037). These data strongly suggest a role for insulin resistance in the decreased GH secretion of obesity and that the blunted GH secretion of central obesity could be the pituitary expression of the metabolic syndrome.

Download Full-text

Association between dietary phylloquinone intake and peripheral metabolic risk markers related to insulin resistance and diabetes in elderly subjects at high cardiovascular risk

Cardiovascular Diabetology ◽

10.1186/1475-2840-12-7 ◽

2013 ◽

Vol 12 (1) ◽

pp. 7 ◽

Cited By ~ 41

Author(s):

Martí Juanola-Falgarona ◽

Jordi Salas-Salvadó ◽

Ramon Estruch ◽

Maria P Portillo ◽

Rosa Casas ◽

...

Keyword(s):

Insulin Resistance ◽

Cardiovascular Risk ◽

Elderly Subjects ◽

Metabolic Risk ◽

Risk Markers ◽

High Cardiovascular Risk

Download Full-text

METABOLIC RISK FACTORS AND THE EFFECT OF ALIROCUMAB ON CARDIOVASCULAR EVENTS IN PATIENTS AFTER ACUTE CORONARY SYNDROME: AN ANALYSIS OF THE ODYSSEY OUTCOMES RANDOMIZED CONTROLLED TRIAL

Journal of the American College of Cardiology ◽

10.1016/s0735-1097(21)01509-6 ◽

2021 ◽

Vol 77 (18) ◽

pp. 150

Author(s):

Petr Ostadal ◽

Philippe Gabriel Steg ◽

Yan Poulouin ◽

Deepak Bhatt ◽

Vera Bittner ◽

...

Keyword(s):

Risk Factors ◽

Randomized Controlled Trial ◽

Acute Coronary Syndrome ◽

Cardiovascular Events ◽

Controlled Trial ◽

Metabolic Risk Factors ◽

Metabolic Risk ◽

Coronary Syndrome ◽

Randomized Controlled

Download Full-text

Very similar cardiometabolic profile in the moderate and high cardiovascular risk classes: a population-based study

European Journal of Preventive Cardiology ◽

10.1093/eurjpc/zwab061.227 ◽

2021 ◽

Vol 28 (Supplement_1) ◽

Author(s):

M Chlabicz ◽

J Jamolkowski ◽

W Laguna ◽

P Sowa ◽

M Paniczko ◽

...

Keyword(s):

Insulin Resistance ◽

Cardiovascular Disease ◽

Cardiovascular Risk ◽

High Risk ◽

Population Based ◽

Low Risk ◽

Public Institution ◽

Population Based Study ◽

The Metabolic Syndrome ◽

Cardiometabolic Profile

Abstract Funding Acknowledgements Type of funding sources: Public Institution(s). Main funding source(s): Medical University of Bialystok, Poland Background Cardiovascular disease (CVD) is a major, worldwide problem and remain the dominant cause of premature mortality in the word. Simultaneously the metabolic syndrome is a growing problem. The aim of this study was to investigate the cardiometabolic profile among cardiovascular risk classes, and to estimate CV risk using various calculators. Methods The longitudinal, population-based study, was conducted in 2017-2020. A total of 931 individuals aged 20-79 were included. Anthropometric and biochemical profiles were measured according to a standardized protocols. The study population was divided into CV risk classes according to the latest recommendation. Comparisons variables between subgroups were conducted using Dwass-Steele-Critchlow-Fligner test. To estimate CV risk were used: the Systematic Coronary Risk Estimation system, Framingham Risk Score and LIFEtime-perspective model for individualizing CardioVascular Disease prevention strategies in apparently healthy people (LIFE-CVD). Results The mean age was 49.1± 15.5 years, 43.2% were male. Percentages of low-risk, moderate-risk, high-risk and very-high CV risk were 46.1%, 22.8%, 13.5%, 17.6%, respectively. Most of the analyzed anthropometric, body composition and laboratory parameters did not differ between the moderate and high CV risk participants, whereas the low risk group differed significantly. In the moderate and high-risk groups, abdominal distribution of adipose tissue dominated with significantly elevated parameters of insulin resistance. Interestingly, estimating lifetime risk of myocardial infarction, stroke or CV death using LIFE-CVD calculator yielded similar results in moderate and high CV risk classes. Conclusion The participants belonging to moderate and high CV risk classes have a very similar unfavorable cardiometabolic profile which may result in the similar lifetime CV risk. This may imply the need for more aggressive pharmacological and non-pharmacological management of CV risk factors in the moderate CV risk population. It would be advisable to consider combining the moderate and high risk classes into one high CV risk class, or it may be worth adding one of the parameters of abdominal fat distribution to the CV risk calculators as an expression of increased insulin resistance. Abstract Figure 1.

Download Full-text